Izicopan, Inflarx’s experimental oral treatment for ANCA-associated vasculitis (AAV), was safe and showed promise for treating the autoimmune disease in a first-in-human trial involving healthy volunteers. That’s according to newly published data from the early clinical trial, which enrolled more than 80 healthy adults. Company researchers noted that…
Discussion
Back in March, I wrote about why I’ve never liked the phrase “lived experience.” The short version: Plain words connect better than institutional ones. If you want to know what someone’s life is like, just ask how it’s going. And there’s really no such thing as a “lived experience.”…
Discussion
A German biopharmaceutical company says it intends to launch two mid-stage clinical trials next year to test its oral treatment candidate izicopan — a next-generation therapy that developer Inflarx says may offer an “improved safety profile” and “more convenient dosing” — in people with ANCA-associated vasculitis (AAV).
Becoming educated and informed about ANCA vasculitis is a good first step. Here you’ll find general information such as the diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your ANCA vasculitis journey.
There is no cure for ANCA vasculitis yet, but here you can find more information about current approved treatments, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
